Pfizer Shares
- All
- News
- Videos
-
Iraq Gets 1.2 Million Pfizer Covid Vaccine Doses Amid Fears Of 4th Wave
Iraq said Saturday it has received 1.2 million doses of Pfizer-BioNTech's COVID-19 vaccine through the Covax sharing scheme, amid fears of a fourth wave in the country.
-
Stocks To Watch In Trade Today: Pfizer India, Reliance Industries, Tata Consumer
List of Stocks in Focus Today: Pfizer India shares are likely be in the limelight after Pfizer became the first pharma company to seek an emergency use authorisation from DCGI for its covid-19 vaccine in India
-
After Pfizer, Serum Institute Of India Seeks Approval For Covid Vaccine
Serum Institute of India, the world's largest vaccine maker by number of doses produced, has sought government approval for emergency use authorisation of the coronavirus vaccine that it is developing with the University of Oxford and British drugmaker AstraZeneca, sources have said.
-
Moderna, Pfizer Share Covid Vaccine Trial Blueprints Amid Pressure
US biotech firm Moderna, one of nine companies in the late stages of clinical trials for a Covid-19 vaccine, became the first to publish the complete blueprints of its study following calls for greater transparency.
-
Pfizer Jumps Over 7% On AstraZeneca Deal
Pfizer entered into a pact with AstraZeneca AB to acquire the 'Neksium' brand in India for Rs 75 crore.
-
Pfizer Concludes Rs 110-Crore Deal With Piramal Enterprises
Drug maker Pfizer on Monday said it has completed the process of transferring four products to Mumbai-based Piramal Enterprises after getting necessary regulatory approvals.
-
AstraZeneca Tanks Almost 11% On Termination Notice For Meronem
AstraZeneca Pharma stock plunged almost 11 per cent as it will stop selling anti-bacterial drug Meronem in India following a global deal by its UK parent to sell its small molecule antibiotics business to Pfizer Inc.
-
Piramal Enterprises To Acquire 4 Pfizer Brands For Rs 110 Crore
Ajay Piramal-led Piramal Enterprises has entered into an agreement to acquire four brands from Pfizer for a consideration of Rs 110 crore.
-
Pfizer Q4 Net Profit Spikes 57% To Rs 67 Crore
Drug firm Pfizer on Friday reported a 56.9 per cent rise in its stand-alone net profit at Rs 66.9 crore for the March quarter.
-
Lupin Leads Selloff in Pharma Shares, Hits 52-Week Low
Lupin shares have been reeling under selling pressure following adverse observations about the company's Goa plant by the US Food and Drug Administration earlier this week.
-
Pharma Stocks Reel Under Heat of Government Action
Pharma stocks were under strong selling pressure for second consecutive day, weighed down by a weekend order from the government banning over 300 drugs.
-
Pfizer, Abbott, Procter & Gamble Shares Hit By Drug Ban
Pfizer shares were headed for their second successive fall on Tuesday following following a ban on its Corex cough syrup. Pfizer shares sank 9 per cent yesterday.
-
Pfizer Shares Tumble 7% as Company Stops Sale of Corex Cough Syrup
Shares of pharmaceutical firm Pfizer on Monday slumped nearly 7 per cent as the company discontinued the manufacture and sale of popular cough syrup Corex with immediate effect.
-
Pfizer Stops Sale Of Corex Cough Syrup, Shares Tumble
Shares in the Indian units of US-based drugmakers Pfizer and Abbott Laboratories fell as much as 5 per cent on Monday after authorities imposed a ban on their codeine-based cough syrups, saying they posed a health risk.
-
Pfizer Shares Zoom Nearly 9% on Allergen Deal
Pfizer investors will be able to opt for cash instead of stock in the combined company in exchange for their shares, provided the aggregate amount of cash to be paid is not less than $6 billion or more than $12 billion.
-
Iraq Gets 1.2 Million Pfizer Covid Vaccine Doses Amid Fears Of 4th Wave
Iraq said Saturday it has received 1.2 million doses of Pfizer-BioNTech's COVID-19 vaccine through the Covax sharing scheme, amid fears of a fourth wave in the country.
-
Stocks To Watch In Trade Today: Pfizer India, Reliance Industries, Tata Consumer
List of Stocks in Focus Today: Pfizer India shares are likely be in the limelight after Pfizer became the first pharma company to seek an emergency use authorisation from DCGI for its covid-19 vaccine in India
-
After Pfizer, Serum Institute Of India Seeks Approval For Covid Vaccine
Serum Institute of India, the world's largest vaccine maker by number of doses produced, has sought government approval for emergency use authorisation of the coronavirus vaccine that it is developing with the University of Oxford and British drugmaker AstraZeneca, sources have said.
-
Moderna, Pfizer Share Covid Vaccine Trial Blueprints Amid Pressure
US biotech firm Moderna, one of nine companies in the late stages of clinical trials for a Covid-19 vaccine, became the first to publish the complete blueprints of its study following calls for greater transparency.
-
Pfizer Jumps Over 7% On AstraZeneca Deal
Pfizer entered into a pact with AstraZeneca AB to acquire the 'Neksium' brand in India for Rs 75 crore.
-
Pfizer Concludes Rs 110-Crore Deal With Piramal Enterprises
Drug maker Pfizer on Monday said it has completed the process of transferring four products to Mumbai-based Piramal Enterprises after getting necessary regulatory approvals.
-
AstraZeneca Tanks Almost 11% On Termination Notice For Meronem
AstraZeneca Pharma stock plunged almost 11 per cent as it will stop selling anti-bacterial drug Meronem in India following a global deal by its UK parent to sell its small molecule antibiotics business to Pfizer Inc.
-
Piramal Enterprises To Acquire 4 Pfizer Brands For Rs 110 Crore
Ajay Piramal-led Piramal Enterprises has entered into an agreement to acquire four brands from Pfizer for a consideration of Rs 110 crore.
-
Pfizer Q4 Net Profit Spikes 57% To Rs 67 Crore
Drug firm Pfizer on Friday reported a 56.9 per cent rise in its stand-alone net profit at Rs 66.9 crore for the March quarter.
-
Lupin Leads Selloff in Pharma Shares, Hits 52-Week Low
Lupin shares have been reeling under selling pressure following adverse observations about the company's Goa plant by the US Food and Drug Administration earlier this week.
-
Pharma Stocks Reel Under Heat of Government Action
Pharma stocks were under strong selling pressure for second consecutive day, weighed down by a weekend order from the government banning over 300 drugs.
-
Pfizer, Abbott, Procter & Gamble Shares Hit By Drug Ban
Pfizer shares were headed for their second successive fall on Tuesday following following a ban on its Corex cough syrup. Pfizer shares sank 9 per cent yesterday.
-
Pfizer Shares Tumble 7% as Company Stops Sale of Corex Cough Syrup
Shares of pharmaceutical firm Pfizer on Monday slumped nearly 7 per cent as the company discontinued the manufacture and sale of popular cough syrup Corex with immediate effect.
-
Pfizer Stops Sale Of Corex Cough Syrup, Shares Tumble
Shares in the Indian units of US-based drugmakers Pfizer and Abbott Laboratories fell as much as 5 per cent on Monday after authorities imposed a ban on their codeine-based cough syrups, saying they posed a health risk.
-
Pfizer Shares Zoom Nearly 9% on Allergen Deal
Pfizer investors will be able to opt for cash instead of stock in the combined company in exchange for their shares, provided the aggregate amount of cash to be paid is not less than $6 billion or more than $12 billion.
